Overview

STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

Status:
Recruiting
Trial end date:
2022-02-27
Target enrollment:
Participant gender:
Summary
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma Pharmacokinetic (PK) of PF-06882961
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer